Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MeiraGTx Holdings (MGTX) Amortization of Deferred Charges (2022 - 2024)

MeiraGTx Holdings posted quarterly Amortization of Deferred Charges of $300000.0 for Q2 2024, little changed year-on-year from $300000.0 in Q3 2023, and little changed on a QoQ basis from $300000.0 in Q1 2024.

MeiraGTx Holdings (MGTX) has 3 years of Amortization of Deferred Charges data on file, last reported at $300000.0 in Q2 2024.

  • For the quarter ending Q2 2024, Amortization of Deferred Charges changed 0.0% year-over-year to $300000.0; the trailing twelve-month figure through Jun 2024 stood at $1.2 million (up 20.0% YoY), and the FY2023 full-year result was $1.1 million, up 175.0% from the prior year.
  • Amortization of Deferred Charges for Q2 2024 stood at $300000.0, roughly flat from $300000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $300000.0 in Q1 2023 and bottomed at $200000.0 in Q3 2022.
  • The 3-year median for Amortization of Deferred Charges is $300000.0 (2023), against an average of $275000.0.
  • The widest annual swing landed in 2023, when Amortization of Deferred Charges jumped 50.0%; it then changed 0.0% in 2024.
  • A 3-year view of Amortization of Deferred Charges shows it stood at $200000.0 in 2022, then surged by 50.0% to $300000.0 in 2023, then changed by 0.0% to $300000.0 in 2024.
  • The last three Amortization of Deferred Charges figures came in at $300000.0 (Q2 2024), $300000.0 (Q1 2024), and $300000.0 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 MeiraGTx Holdings 856.58 Mn 790.65 Mn 74.89 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2024 300,000.00
Jun 30, 2024 300,000.00
Mar 31, 2024 300,000.00
Mar 31, 2024 300,000.00
Dec 31, 2023 300,000.00
Dec 31, 2023 300,000.00
Sep 30, 2023 300,000.00
Sep 30, 2023 300,000.00
Jun 30, 2023 300,000.00
Jun 30, 2023 300,000.00
Mar 31, 2023 300,000.00
Mar 31, 2023 300,000.00
Dec 31, 2022 200,000.00
Dec 31, 2022 200,000.00
Sep 30, 2022 200,000.00
Sep 30, 2022 200,000.00